Ozempic maker Novo Nordisk is replacing its chairman and shaking up its board as it struggles to regain lost market share in the weight-loss drug boom
NegativeHealth

Novo Nordisk, the maker of Ozempic, is undergoing significant leadership changes as it aims to recover lost market share in the competitive weight-loss drug sector. The company's controlling shareholder plans to replace seven directors, including the chairman, highlighting the urgency of the situation. This shake-up is crucial as the company faces increasing pressure from competitors and needs to realign its strategy to maintain its position in the market.
— Curated by the World Pulse Now AI Editorial System